CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV

作     者：Cheng Peng Mengji Lu Dongliang Yang 

作者机构：Department of Infectious DiseasesUnion HospitalTongji Medical CollegeHuazhong University of Science and Technology Institute of VirologyUniversity Hospital of EssenUniversity of Duisburg-Essen 

出 版 物：《Virologica Sinica》 (中国病毒学（英文版）)

年 卷 期：2015年第30卷第5期

页      面：317-325页

核心收录：

学科分类：0710[理学-生物学] 1007[医学-药学(可授医学、理学学位)] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：supported by National Natural Science Foundation of China (NSFC8120232,NSFC81461130019) Transregio-SFB (TRR) of the Deutsche Forschungsgemeinschaft (DFG TRR60) 

主　　题：hepatitis B virus(HBV) CRISPR/Cas9 covalently clos 

摘      要：Hepatitis B virus(HBV) infection remains a major global health problem because current therapies rarely eliminate HBV infections to achieve a complete cure. A different treatment paradigm to effectively clear HBV infection and eradicate latent viral reservoirs is urgently required. In recent years, the development of a new RNA-guided gene-editing tool, the CRISPR/Cas9(clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9) system, has greatly facilitated site-specific mutagenesis and represents a very promising potential therapeutic tool for diseases, including for eradication of invasive pathogens such as HBV. Here, we review recent advances in the use of CRISPR/Cas9, which is designed to target HBV specific DNA sequences to inhibit HBV replication and to induce viral genome mutation, in cell lines or animal models. Advantages, limitations and possible solutions, and proposed directions for future research are discussed to highlight the opportunities and challenges of CRISPR/Cas9 as a new, potentially curative therapy for chronic hepatitis B infection.